Precision BioSciences Inc. (NASDAQ:DTIL) shares traded 4.13% higher at $1.01 on Wall Street last session.
In accordance with the data, 10 analysts cover Precision BioSciences Inc. (NASDAQ:DTIL). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $17.00 and a low of $1.00, we find $6.00. Given the previous closing price of $0.97, this indicates a potential upside of 518.56 percent. DTIL stock price is now -22.80% away from the 50-day moving average and -41.42% away from the 200-day moving average. The market capitalization of the company currently stands at $111.00M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 3 analysts and a buy by 6. Brokers who have rated the stock have averaged $6.33 as their price target over the next twelve months.
With the price target of $7, BMO Capital Markets recently initiated with Outperform rating for Precision BioSciences Inc. (NASDAQ: DTIL). , while ‘BTIG Research’ rates the stock as ‘Buy’.
In other news, Amoroso Michael, President and CEO sold 11,006 shares of the company’s stock on Oct 17. The stock was sold for $14,528 at an average price of $1.32. Upon completion of the transaction, the President and CEO now directly owns 13,202 shares in the company, valued at $13334.02. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 23, Chief Financial Officer Kelly John Alexander bought 8,200 shares of the business’s stock. A total of $10,086 was incurred on buying the stock at an average price of $1.23. This leaves the insider owning 162,938 shares of the company worth $0.16 million. Insiders disposed of 39,688 shares of company stock worth roughly $40084.88 over the past 1 year. A total of 1.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DTIL stock. A new stake in Precision BioSciences Inc. shares was purchased by BRIDGEWAY CAPITAL MANAGEMENT, LLC during the first quarter worth $224,000. VERICREST PRIVATE WEALTH invested $156,000 in shares of DTIL during the first quarter. In the first quarter, WEISS MULTI-STRATEGY ADVISERS LLC acquired a new stake in Precision BioSciences Inc. valued at approximately $101,000. ZACKS INVESTMENT MANAGEMENT acquired a new stake in DTIL for approximately $36,000. VIRTU FINANCIAL LLC purchased a new stake in DTIL valued at around $27,000 in the second quarter. In total, there are 158 active investors with 47.40% ownership of the company’s stock.
Precision BioSciences Inc. (NASDAQ: DTIL) opened at $0.9700 on Thursday. During the past 12 months, Precision BioSciences Inc. has had a low of $0.95 and a high of $8.07. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.70, and a quick ratio of 3.70. The fifty day moving average price for DTIL is $1.3083 and a two-hundred day moving average price translates $1.7243 for the stock.
The latest earnings results from Precision BioSciences Inc. (NASDAQ: DTIL) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.46, missing analysts’ expectations of -$0.41 by -0.05. This compares to -$0.19 EPS in the same period last year. The company reported revenue of $7.36 million for the quarter, compared to $24.04 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -69.37 percent. For the current quarter, analysts expect DTIL to generate $5.97M in revenue.
Precision BioSciences Inc.(DTIL) Company Profile
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
